Cigarette paper increase of cigarette burning rate 68:91 Cigarettes definition and processing 73:175 and development of esophageal neoplasms 71:12, 293 flavor, terpenoids as source of 64:52 low nicotine, and respiratory symptoms 64:289 low nicotine, ciliastatic effect of 64:268 modified, effect on respiratory symptoms and ventilatory capacity 73:37, 38 portion smoked, dosage score as function of 67:15 similarities with little cigars 73:224,225 tar and nicotine content 72:142,143 tar levels of, relationship to lung neoplasm development 71:275,276 taxation 69:4.57 see also Cigarettes, filter; Cigarettes, lownicotine; Cigarettes, non-nicotine; Cigarettes, non-tobacco Cigarettes, daily consumption aortic aneurysm mortality by 69:16 and atypical nuclei in larynx 69:59 average, dosage score as function of 67:15 bladder neoplasms mortality rates by 67:155 bronchitis mortality ratios by 67:90 coronary disease incidence rates 67:58;69:15;21-24 coronary disease mortality rates by 67:51:69:13 coronary disease mortality ratios by 67:49 coronary disease mortality ratios for male smokers by 67:48 digestive tract neoplasm mortality rates by 67:147 effect on lung neoplasm mortality in Poland 72:61.62 esophageal neoplasm mortality ratios by 67:150 increase in, by women 64:363 laryngeal neoplasm mortality rates by 67:147 liver cirrhosis mortality rates by 67:184 liver cirrhosis mortality ratios by 67:184

lung neoplasm morbidity rates by 67:33-34 lung neoplasm mortality rates 67:135-137 lung neoplasm mortality ratios 67:34, 135-140 mouth neoplasm mortality rates by 67:146 mouth neoplasm mortality ratios by 67:146 pancreatic neoplasm mortality rates in men by 67.159 pancreatic neoplasm mortality ratios in men by 67:159 peptic ulcer mortality rates in male smokers by 67:182 per capita 64:26, 45, 46, 185 pharyngeal neoplasm mortality rates by 67:146 pharyngeal neoplasm mortality ratios by 67:146 prevalence of 64:361-374 respiratory tract neoplasm mortality rates by 67:147 stomach neoplasm mortality rates by 67:157 stomach neoplasm mortality ratios by 67:157 tracheal neoplasm mortality rates by 67:147 in tuberculars 64.277 urogenital neoplasm mortality ratios for male smokers by 67:154 Cigarettes, filter decrease in tar yields 68:91 effect on respiratory symptoms 73:55 increase in 64:46 and polonium-210 content in tobacco smoke 68:92 production of, in U.S., by year 64:46 and risk of lung neoplasms 69:57; 75:44 summary of previous findings 75:4 vs. nonfilter, and risk of lung neoplasms 74:40.41 vs. nonfilter, comparison of safety 69:57 vs. nonfilter, effect on sputum production 73:37, 38 Cigarettes, low-nicotine respiratory symptoms from 64:268

Cigarette smoke see Smoke, cigarette Cigarette smokers see Smokers, cigarette Cigarette smoking see Smoking Cigarettes, non-nicotine effect on apexcardiogram 72:21 effect on carboxyhemoglobin levels 73:17,18 Cigarettes, non-tobacco 64:59 Cigars definition and processing 73:175, 176 per capita consumption 64:26,45 Cigars, little chemical composition of 73:224, 225, 228 evaluation of potential public health impact 73:222-228 shipment for domestic consumption (1970-1972) 73:222-224, 227 similarity to cigarettes 73:224, 225 sugar and pH differences with large cigar and cigarettes 73:222-224 tar and nicotine content 73:224-226, 228 Cigar smoke see Smoke, cigar Cigar smokers see Smokers, cigar; Smokers, cigar and pipe Ciliary activity 64:61 clearance mechanism by 64:267,268 effect of cigarette smoke in animals 68:71,72 effect of nitrogen dioxide, in rats 74:103 effect of pipe/cigar smoke vs. cigarette smoke in cats 73:217,218 effect of smoke on 64:27, 34, 35, 61, 168, 169, 170, 172, 173, 267; 67:107-108; 69:42 effect of smoking on 74:101,102 loss of, in smokers 64:168, 169, 170, 172, 173 morphological changes in cilia 64:267,268,271 transport 64:61, 267, 268 Ciliary depressants 64:27, 33, 34, 61, 267, 268 acrolein as 64:267,268 ammonia as 64:268

cigarette smoke as 64:33, 35, 370 formaldehyde gas as 64:268 gas phase as 64:34 hydrogen cyanide as 64:268 nicotine as 64:268 nitrogen dioxide as 64:268 ozone as 64:268 sulfur dioxide as 64:268,295 Ciliatoxic agents acetic acid 67:108 acrolein 67:107 in cigarette smoke 67:107 crotonaldehyde 67:108 cyanides 67:107 effect on adenosine triphosphatase 67:108 effect on oxidative enzymes 67:108 formaldehyde 67:107 formic acid 67:108 phenols 67:108 propionic acid 67:108 Circulatory diseases 64:113 Circumcision 64:224 Clofibrate and reduction in risk of sudden death in cigarette smokers 75:32 Closing volume abnormalities as indicator of small airways disease, in smokers vs. nonsmokers 74:84-87; 75:71, 72 Coal dust effect on pulmonary function in smokers vs. nonsmoker 73:41-43 effect on respiratory symptoms in smokers vs. nonsmokers 73:41-43 Coal gas workers 64:232 lung neoplasms in 64:193 Coal miners pneumoconiosis and 72:42-44 respiratory function tests in 64:289, 293, 294

respiratory symptoms in 64:298, 299 Coal tar benzo(a)pyrene content of 64:148 neoplasm induction by 64:33, 147, 167, 229 Cocaine 64:349 Coca leaves 64:349 Cocarcinogens 64:33, 58, 142, 144, 145 benz(a)anthracene as 64:58 carboxylic acids as 67:131 croton oil as 64.58 fatty acids as 64:58.59 nickel carbonyl as 69:62 phenols as 64:54, 58, 59; 67:31 in tobacco smoke 64:33;69:61 in tobacco tars 67:131 Cocoa 64:349 Coffee drinking 64:349 angina pectoris, smoking, and 74:8 myocardial infarction, smoking and, in smokers vs. nonsmokers 74:8;75:19,20 Cognition and smoking habit 67:189-191 Cologne, autopsy records in **64**:150 Colonic polyposis 64:191 Combustion temperature effect on tumorigenic activity of pipe and cigarette tobacco 73:210, 211 Common colds 64:276 Compensatory behavior, smoking as 64:372 Congenital malformations maternal smoking and 72:87; 73:136, 137 Congestive heart failure 64:320 Connecticut Cancer Registry 64:127,128 data from 64:135 figures on age-adjusted larynx neoplasm incidence 71:277

figures on incidence of oral neoplasms 71:284 Constitutional hypothesis 64:190, 191, 192, 193 refutation of 64:192 relationship to CHD and smoking 71:48-49, 105-106 Contraceptives, oral incidence of stroke and, in women smokers vs. nonsmokers 74:16.17 smoking and 72:26 thrombophlebitis and 72:26 Control populations bias in selection of 64:181, 217, 231 Copenhagen neoplasm study in 64:220, 222, 224 **Tuberculosis Station** 64:141 Copper 64:193 nitrate 64:60 sulfate 64:354 Coppersmiths 64:134 Cornfield method 64:155, 159, 160 Cornsilk smoking, lack of arterial epinephrine level increase 71:57 Coronary circulation 64:318;68:41-43 Coronary diseases 64:8, 29, 36, 38 103, 106, 108, 317, 320-327, 384, 385 age-adjusted rates in smokers 71:23 by amount smoked 69:12-13, 18 arteriosclerotic, mortality rates in U.S. 71.21 associated risk factors and smoking 74:17 atherosclerosis 64:320 atherosclerosis, effects of smoking on 71:4,63 autopsy studies 72:19, 20; 74:4 and behavior 67:57 blood pressure of smokers vs. nonsmokers 71:43.47 carbon dioxide effects on oxygen uptake in 71:62 carbon monoxide and 74:4

carboxyhemoglobin levels and 72:27
cross-sectional study in Bergen, Norway
72:16 death ratios of paired combinations of
high risk 71:25
effect of coffee drinking and cigarette
smoking 75:20
effect of norepinephrine levels 68:38
effect of smoking on blood circulation in
67:26, 61-62 effect on blood circulation
67:62-63 effect on blood pressure
67:54 epidemiological studies
64:320, 321, 322; 69:25; 72:14-16;
73:4-11; 75:14, 15 etiology of
64:320, 321, 322 excess deaths in
64:113
experimental studies 73:13-19
heredity as a factor 72:18
high blood pressure in 64:38
high serum cholesterol in
64:38 incidence and education level
68:24 incidence and mortality rates in former
smokers 71:46, 47-48
incidence in European vs. American men 73:9
incidence in farmers vs. nonfarmers by
smoking habit 73:7
incidence in Hawaiian men of Japanese
ancestry 73:10
incidence in Japanese male smokers vs. nonsmokers
68:17
incidence in lawyers 68:25
incidence in male bank employees in Brussels, Belgium
73:10
incidence in males by smoking habits or physical activity
68:20, 25 incidence in male smokers vs. nonsmok-
ers
68:17, 18, 20, 23, 25, 27, 28, 37 incidence in men in Yugoslavia
73:9 incidence in men under 60, in New
South Wales 74:6
incidence in men with and without
ventricular premature beats

incidence in middle-aged men from various countries 74:6 incidence in miners in Sardinia 73:10 incidence in Minnesota men by age and smoking habit 72:14-16 incidence in pipe and cigar smokers 73:215, 216 incidence in smokers vs. nonsmokers, Peoples Gas Co. Study 74:6,7 incidence in smokers vs. nonsmokers, Stockholm Prospective Study 74:6 incidence in tribal population area, New Guinea 74:9 incidence in twins 68:29 incidence in white males by body weight and smoking habit 73:5 incidence in whites vs. blacks in Evans County, Georgia 73:4,5 incidence in women, smokers vs. nonsmokers 74:9,10 incidence of, relation to angina pectoris 67:53 incidence of, relation to blood cholesterol levels 67:58 incidence of, relation to blood pressure 67:58 incidence of, relation to body weight 67:58 incidence of, relation to electrocardiographic abnormalities 67.58 incidence of, relation to hemoglobin levels 67:58 incidence of, relation to myocardial infarct 67:53 incidence of, relation to socioenvironmental stress 67:56 incidence rates, by age 67:54, 57-58; 68:21; 69:21-22, 24 incidence rates, by amount smoked 67:54, 57-58 incidence rates, by behavior type 69:20, 24 incidence rates, by smoking and other risk factors 69:23 incidence rates, by smoking history 69:21-24 incidence rates in men 67:65;69:21-22 incidence rates in twins, smokers vs. nonsmokers

67:59

74:4-6

incidence rates, smokers vs. nonsmokers 69:18, 20-22 in India 73:11 infarction in NYC pipe and cigar smokers 71:32, 38-39 infarction, relationship to physical activity, smokers vs. nonsmokers 71:44 interaction of smoking and other risk factors 72:16-18:73:4-11 in Irish smokers vs. nonsmokers 68:18 morbidity ratios 67:59;69:19 morbidity ratios, and blood pressure 67:55 morbidity ratios, and lung function 67:56 morbidity ratios, by age 67:54 morbidity ratios, by blood cholesterol levels 67:55 morbidity ratios, by personality characteristics 67:57 morbidity ratios, by sociocultural mobility status 67:57 morbidity ratios, in New Delhi, India 72:16 morbidity, relationship of smoking to 71:32-35, 37, 39, 93-97 mortality and morbidity retrospective studies 71:40, 93-97 mortality rates 64:25, 29, 32, 38, 39, 184, 320, 321, 324;67:8,25-26 mortality rates among former college students 69:16, 18 mortality rates and per capita cigarette consumption in several countries 72:16 mortality rates, by age 67:25, 28, 47, 49-51; 69:13-14 mortality rates by blood pressure 69:14 mortality rates by relative weight 69:14 mortality rates, by sex 67:25, 27, 28, 47, 49-50; 69:13-14 mortality rates, by smoking 67:25, 28, 49-51; 69:13-14 mortality rates, effect of associated diseases on 67:51-52 mortality rates, effect of cessation of smoking on 67:25, 27-28, 50 mortality rates, ex-smokers by smoking history 67:51

mortality rates in heavy smokers 64:322 mortality rates in hypertensives vs. nonhypertensives 71.42 mortality rates in industrial workers 64:323 mortality rates in Japanese men and women by cigarette consumption and age started smoking 73:7.8 mortality rates in longshoremen 72:14 mortality rates in obese vs. nonobese 71:45 mortality rates in smokers vs. nonsmokers 71:21-22, 24, 26-29 mortality rates in smoking men in Finland 73:9 mortality rates in United States 67:47;68:16 mortality rates in, with increased carbon monoxide 71:62 mortality rates of cigarette smokers from, AHA pooling project 71:28, 30, 39 mortality rates of paired combinations of high risk 71:25 mortality rates of U.S. veterans 71:26,38 mortality rates, relationship to electrocardiographic findings 71:42 mortality ratios, by age 67:25, 26, 28, 49-50, 52; 69:13 mortality ratios, by age and blood pressure 67:53 mortality ratios, by age and smoking history 67:51-52 mortality ratios, by amount smoked 67:48-49; 69:13 mortality ratios, by sex 67:25, 28; 69:13-14 mortality ratios, by smoking history 67:25,28 mortality ratios, effect of associated diseases 67:51-52 mortality ratios in pipe and cigar smokers 73:215,216 and multiple risk factors 68:28-30 in Nepal 73:11 in New Zealand 73:11 nicotine and 74:13 nicotine effect on coronary blood flow in 71:58

obesity in 64:38 occlusion in 64:320 occupational risks in 64:321, 322 pathophysiology of, effect of carbon monoxide exposure 74:10 and personality characteristics 64:321, 326; 67:57 predisposing characteristics 67:58 prevalence of 64:320, 321 relationship of blood pressure and smoking 71:45,47 relationship of heart rate and smoking 71:45,47 relationship of physical activity and smoking 71:41,43,44 relationship of triglycerides to 71:65 relationship to constitutional makeup and smoking 71:48-49, 105-106 relationship to ECG abnormalities and smoking 71:45,47 relationship to obesity and smoking 71:43-45 retrospective studies in Goteborg, Sweden 72:16 retrospective studies in Prague, Czechoslovakia 72:16 risk factors 71:23-24, 40-41 risk factors and personal characteristics 68:26 role of glucose metabolism 68:40,41 in Seventh Day Adventists 64.322 smokers' age effects on development 71:27, 39 in smokers vs. nonsmokers 68:26, 42, 43 in smokers with predisposing factors 71:24 smoking and 67:26, 54, 64-65; 69:3-5, 11, 20; 71:5 smoking and, in individuals under 40 years 73:10 smoking and, in myocardial ischemic patients in Italy 73:10 smoking as cause of death 67:25-27 smoking as etiologic agent in 67:26, 54, 62, 65, 66; 69:11; 72:1, 2, 13, 14

smoking in thrombus formation 67:26.64-65 smoking risk factor 71:8 sudden death, and smoking 67:53;71:52 summary of previous findings 68:16; 75:4, 7 summary of relationship to smoking 74:3, 4, 19 symptoms of 64:320 twin studies 72:18 in women 64:321 see also Angina pectoris; Arteriosclerosis; Atherosclerosis; Cardiovascular diseases Coronary Drug Project Research Group epidemiologic study of smoking and CHD 74:4-6 Coronary heart disease see Coronary diseases Coronary vessels effect of cigarette smoking on 67:65 Coronene 64:147 Cor pulmonale and chronic obstructive pulmonary disease 74:76 Cotinine 64:71 desmethyl-64:72 effect on rats and mice 69:61-62 in experimental induction of bladder adenomas 69:64 methonium ion, structure of 64:72 Cough 64:280, 281, 282, 283 chronic 64:27, 280, 281, 282, 283, 299, 302 chronic, and cigarette smoking in males 68:69 chronic, in women 64:282,285 effect of air pollution and smoking 64:297;74:90,91 effect of asbestos exposure in smokers vs. nonsmokers 73:41 effect of coal dust exposure in smokers vs. nonsmokers 73:41,42 effect of filtered cigarettes 73:55 effect of modified cigarettes 73:38 epidemiology of 67:97 ex-smokers vs. nonsmokers 67:98

of parental smokers, and respiratory symptoms in children 75:103,105 prevalence in cement and rubber industry workers, smokers vs. nonsmokers 74:95,96 prevalence in pipe and cigar smokers 73:220, 221 prevalence in smoking vs. nonsmoking women in Bordeaux, France 73:36 prevalence of 64:38, 280, 283, 284, 289, 291, 301, 302 prevalence of among smokers 67:103 prevalence of, in smoking-discordant twin pairs 67:103 respiratory function in presence of 64:291,292 in school-age smokers vs. nonsmokers 75:62 smokers vs. nonsmokers 67:29; 72:40 and smoking 64:297;67:97 and smoking, by sex 67:98 and sputum 64:283-286 traumatic injury from 64:279 Coumarin 64:145 Creosote oil carcinogenic activity of 64:147 Cresols in cigar, pipe, and cigarette smoke 73:177 as probable contributors to health hazards of smoking 72:144 suspected carcinogenic agent of cigarette smoke 71:266 Crotonaldehyde ciliatoxic agent 67:108 in tobacco smoke 67:108 Croton oil 64:58 Crotononitrile as suspected contributor to health hazards of smoking 72:145 Cuba laryngeal neoplasms in 64:205, 207 laryngeal neoplasms in, relationship to tobacco use 71:356 oral neoplasms in, by type of smoking 64:200, 201 oral neoplasms in, relationship of tobacco use 71:364

Current Population Survey of 1955 64:177,180,186 Curschmann's spirals in sputum of smokers 69:39-40 Customs and Excise Act of 1952, Great Britain 64:62 Cyanides detoxification, in pregnant smokers vs. nonsmokers 73:119 in tobacco amblyopia etiology 67:40: 71:14, 435-436: 72:6 in tobacco smoke 67:40 in tobacco smoke, and optic atrophy 67:183 toxicity, potentiation by vitamin B12 in tobacco amblyopia 67:183 and vitamin B deficiency in tobacco amblyopia 67:40 Cysteine inhibition of smoke cytotoxic action on macrophages 69:42 Cystitis 64:224 Cytochrome oxidase 64:266 Cytologic studies exfoliative, and lung neoplasm diagnosis 75:47 macrophage function and smoking 74:104,105 Czechoslovakia 64:205 laryngeal neoplasms in, relationship to tobacco use 71:354,357 laryngeal neoplasms in, retrospective study of 64:206 serum lipid difference in smokers vs. nonsmokers 71:101 Danish Cancer Registry 64:141, 186, 220 **Danish Morbidity Study** 64:224 Data collection methods in retrospective studies 64:206, 214, 215, 226 DDT 64:145 as suspected contributor to health hazards of smoking 72:65, 145 Death certification limitations of, in health statistics 64:101, 127 neoplasm diagnosis in 64:128

Death Registration Act 64:127 Deaths, accidental 64:39, 344, 345 Deaths, sudden from cardiovascular disease 68:36,42 incidence in men with and without ventricular premature beats 74:5 incidence in pipe and cigar smokers 73:215 incidence in women, smokers vs. nonsmokers 74:9, 19 rate by smoking, cholesterol, and blood pressure, 69:17 reduction of risk of, in cigarette smokers, using clofibrate 75:32 smoking as a risk factor 74:4-6, 19 Defense mechanisms 64:264 Demographic factors in smoking 64:361-365 Denmark advertising curtailment in 64:8 atherogenic effect of carbon monoxide and hypoxia 71:64 bladder neoplasms in 64:219, 220, 221 bladder neoplasms in, methods and results in retrospective studies of smoking and 71:381,383 carbon monoxide effects on human blood lipids in 71:129 carbon monoxide effects on rabbit blood lipids in 71:129 coronary mortality in 64:320 cough prevalence in 64:281 Danish Cancer Registry 64:141, 186, 220 Danish Morbidity Study 64:224 lung neoplasm mortality in 64:176 respiratory function tests in 64:291 serum lipid differences in smokers vs. nonsmokers in 71:102 twins in, angina pectoris in smokers vs. nonsmokers 71:51 Deoxyribonucleic acid see DNA Dermatitis among tobacco workers 72:111

Dermatologists coronary disease incidence in 64:322 Dextroamphetamine 64:352 Diabetes mellitus 64:326 effect on CHD in smokers 71:24 relationship with cigarette smoking in peripheral vascular disease 71:72 risk in mortality from CVD 71:67 Diarrhea smoking and 64:71 Dibenz(a,h)acridine 64:56 carcinogenicity 67:127 carcinogenic properties in cigarette smoke from 71:265 pyrolytic formation of 64:59 structural formula of 64:59 Dibenz(a,j)acridine carcinogenicity 67:127 carcinogenic properties in cigarette smoke from 71:265 pyrolytic formation of 64:59 structural formula of 64:56 in tobacco smoke 67:127 Dibenzanthracene tumor induction by 64:143, 167 Dibenz(a,c)anthracene carcinogenicity, as component of cigarette smoke 72:66 Dibenz(a,h)anthracene carcinogenicity 67:127 carcinoma induction by 64:229 structural formula of 64:56 7H-Dibenzo(c,g)carbazole carcinogenic effect in laboratory animals 73:79 carcinogenic effect on respiratory tract in hamsters 72:66,67 carcinogenicity, as component of cigarette smoke 67:127;71:265;72:66,67 structural formula of 64:56 Dibenzo(a,i)pyrene 64:33, 57 carcinogenicity

67:127

structural formula of 64:26 Dicarbonyl compounds 64:53 Dieldrin 64:62 Diet influence of, in coronary disease 64.322 intervention and cholesterol levels in postinfarction patients 68:23 and peptic ulcer 67:182 and smoking 67:66 and smoking, effect on blood lipids 73:12 as test constant 64:224 tobacco amblyopia 72:6 Diethylnitrosamine suspected carcinogenic properties in cigarette smoke from 71:265 Digestive tract neoplasms mortality, and smoking 67:10, 147 Digital blood flow effect of smoking 64:318 Digital temperatures effect of smoking 64:318 Dihydric alcohols 64:52 Dimethylamine as suspected contributor to health hazards of smoking 72:145 9-10-Dimethyl-1, 2-benzanthracene 64:203 7, 12-Dimethylbenz(a)anthracene effect on oral mucosa in hamsters 72:70 **Dimethylnitrosamine** suspected carcinogenic properties in cigarette smoke from 71:265 Dipalmityl ketone 64:53 Dipentene 64:52 2,3-Diphosphoglycerate effects of carbon monoxide on 71:60-61 Disability of emphysema patients 68:66 higher rates of smokers 68:7 DNA alteration, and oral neoplasm carcinogenesis 68:101 binding of polycyclic hydrocarbons to 73:86, 87

effect of aromatic hydrocarbons on 69:61 effect of cigarette smoke on synthesis 69:62-63 increases in smokers' oral epithelial cells 71:288 levels in mice lung exposed to cigarette smoke 71:161 Dogs atherogenic effects of nicotine in 71:120 bladder neoplasms in, fed 2-naphthylamine 71:296 bradycardia and tachycardia in, following nicotine injection 71:57-58 bronchogenic carcinoma induction in, from cigarette smoke inhalation 71:269.270 cigarette smoke instillation or implantation effects on tracheobronchial tree of 71:268,347 death in, causes from cigarette smoke inhalation 71:271 effect of cigarette smoke on pulmonary clearance in 71:164,170 epinephrine release in 64:318, 319 experimental neoplasm induction in 64:146, 165, 189 fetal bronchial tubes of, effect of cigarette smoke on 71:345 lung neoplasms following cigarette smoke inhalation 71:239.277 lung neoplasms in, types and lobes where found 71:269, 272-273 lungs of, cigarette smoke effects on surfactant activity 71:172, 225 myocardium, nicotine effects on 71:58 neoplasm development in smoking, percentages of 71:274 nicotine effect on 64:71, 318, 319 ozone effect on 64:295, 296 pulmonary histological changes in cigarette smoke inhaling 71:158, 159-160 respiratory tract of, cigarette smoke inhalation effects on 71:268, 352, 353 smoke deposition in 64:265 smoke-induced bronchoconstriction in, atropine effects 71:163

smoking and nicotine effects on blood lipids in 71:127-128 smoking and nicotine effects on cardiovascular function in 71:107-112 smoking and nicotine effects on catecholamine levels in 71:119 Doll & Hill study 64:324 Donkeys effect of cigarette smoke on pulmonary clearance in 71:164, 171 Dorn study 64:324 Dosage measure of, in light and heavy smokers 67:14-15 measure of, in men and women 67:14-15 and mortality among women smokers 67:25 nicotine and tar content of cigarette smoke as measurement of 67:15 score, for smoking 67:14-15 smoking exposure 67:25 Driving habits and coronary disease 64:322 Drug addiction 64:350, 351, 352 definition of 64:351 distinction from drug habituation 64:351 psychology of 64:353 Dry mouth 64:354 Dublin lung neoplasm mortality in 64:195 Ducks cigarette smoke instillation or implantation effects on tracheobronchial tree of 71:346 clearance products in 64:269 Duodenal ulcers 64:8, 337, 340 mortality rates in 64:37 mortality ratios in 64:103.337 mortality ratios in male cigar and pipe smokers 73:222 nicotine induced, in cats 73:158, 159 post-operative complications in smokers vs. nonsmokers 73:157

potentiating action of nicotine, in animals 73:161-163 prevalence in smokers, mechanism of action 73:160 smoking and 72:6, 97, 98 Dust exposure 64:298, 299 bronchitis and 73:44 COPD development from 71:153, 218 as occupational hazard 73:43, 44 in smokers vs. nonsmokers, by race and sex 75:69.70 smoking and 73:44 smoking and, as risk factors in bronchitis development 74:93, 94 smoking and, as risk factors in byssinosis development 74:94-96; 75:68 Dysphoria 64:350 Dyspnea 64:286 prevalence in cigar and pipe smokers 73:220, 221 Ear neoplasm 64:147 Edentulism smoking and 69:87;72:6 Educational level 64:100, 101 and incidence of CHD, in males 68:24 smoking prevalence by 64:363 Egypt relationship of human pulmonary histology and smoking in 71:163 Electrocardiograms abnormalities, and CHD 67:58;68:29;71:42,45,47 effect of smoking 64:319;71:45,47;73:13 effect of smoking, in middle-aged Dutch men 73:12 effect of smoking, in young military recruits in Poland 73:12 Electroencephalograms nicotine effect on 64:70 placebo effect on 64:70

smoking effect on 64:70 Electrophoresis use in determining serum level of alpha-1-antitrypsin 71:151 Emotional stress 64:373, 374 Emphysema 64:35, 38, 277-294, 302 air pollution in 64:297 alpha-1-antitrypsin deficiency and 71:150, 151; 72:44; 74:87-90 alveolar destruction in 64.294 asthmatic form of 64:294 autopsy studies, in smokers vs. nonsmokers 75:74-76 bronchitic form of 64:294 and bronchitis mortality rates, for men by amount smoked 67:93 and bronchitis mortality ratios, by age, amount smoked, and sex 67:94 and bronchitis mortality ratios, for men by amount smoked 67:93 bronchitis relation to 64:278, 279, 280 cadmium exposure in etiology of, in animals 74:104 cigarette smoking effects on 71:9 definition of 64:278;67:89;71:139 development in dogs following cigarette smoke inhalation 71:271 development of, relation of cadmium in smoke to 71:154 diagnosis of 64:278, 279, 280; 67:90 disability payments in U.S. 68:66 dyspneic form of 64:297 epidemiology of 64:280-294 excess mortality from 64:25,277 experimentally induced in smoking dogs 72:46 grade II or III, smokers vs. nonsmokers 71:162 in horses 69:40 hypersensitivity in development of 67:111 incidence in cigar/pipe smoking coal miners vs. cigarette smokers and nonsmokers 73:217

morbidity, and cigar smoking 67:99 morbidity, and pipe smoking 67:99 morbidity, and smoking 67:3, 22, 29-30, 96-98 morbidity, body constitution as a factor in 67:30 morbidity, heredity as a factor in 67:30 mortality, and cigar smoking 67:30 mortality, and pipe smoking 67:30 mortality, effect of cessation of smoking on 67:29 mortality, effect of cigarette smoking on 71:175 mortality rates 64:25, 29, 301; 67:29, 90-93; 68:66; 71:139 mortality ratios 64:103, 293; 67:8, 90 mortality ratios, and smoking 67:3, 91 mortality ratios, by amount smoked 67:90-93 mortality ratios, by sex in United States 67:91 mortality ratios, in cigar smokers 67:94 mortality ratios, in male pipe and cigar smokers 73:217, 219 mortality ratios, in pipe smokers 67:94 nonsmoker prevalence of 64:297 occupational exposure in 64:298, 299, 300, 302 pathogenesis of 69:38-40 phases of 64:294 pigment deposition in 64:272, 273 premature development and smoking, autopsy studies 74:97 prevalence in males by smoking category, at autopsy 73:48 prevalence in pipe/cigar and cigarette smokers vs. nonsmokers, autopsy studies 73:45,46 prevalence in smokers vs. nonsmokers 73:55 prevalence rates in U.S. 74:75 prospective studies on 64:293 pulmonary function studies and 74:80 respiratory symptoms, body constitution as a factor in 67:30, 102-103, 108-109

respiratory symptoms, by smoking classi- fication 67:99	coronary diseases and smoking 69:12-25; 72:14-16; 73:4-13, 23; 75:14, 15
respiratory symptoms, heredity as a fac- tor in	esophageal neoplasms and smoking 72:70, 71
67:30, 102-103, 108, 111 respiratory symptoms, in pipe smokers	laryngeal neoplasms and smoking 69:58-60; 72:68
67:99	lung neoplasms and smoking
respiratory symptoms, in smokers 64:27; 67:99; 68:74	69:55-56; 72:60-65; 73:68-72; 74:37;75:44
in smokers vs. nonsmokers, autopsy studies	lung neoplasms, by age and sex
73:45-47	68:94-99 lung neoplasms, in Iceland
smoking and etiology of $64:28 = 294 = 202;  67:20:21 = 06$	68:94, 95
64:38, 294, 303; 67:30-31, 96, 104-107, 110-111; 69:37-38; 72:37; 74:87-90	lung neoplasms, in Japan 68:95, 96
summary of previous findings on rela-	lung neoplasms, in Switzerland 68:95
tionship to smoking	maternal smoking and outcome of preg-
74:75-78; 75:5, 7, 61, 62 Emphysema Registry	nancy 69:77-80; 72:83-87
64:294	oral neoplasms and smoking
Endrin 64:145	69:58; 72:68-70; 74:53
as suspected contributor to health haz-	pancreatic neoplasms and smoking 69:60-61; 72:74; 74:57
ards of smoking	peptic ulcer and smoking
72:145 Enzymes	73:155-157
activity, effect of smoking	urinary tract neoplasms and smoking 69:60
71:165	Epiglottis
adenosine triphosphatase, effect of cilia- toxic agents on	laryngeal neoplasms 64:212
67:108	Epinephrine
aryl hydrocarbon hydroxylase activity in placentas at childbirth	64:318 effect in thrombus formation
71:410	67:64-65
aryl hydroxylase, effect of nickel in	effect of nicotine
cigarette smoke on induction 71:257	75:29 levels in arteries, cigarette smoking ef-
benzo(a)pyrene hydroxylase, activity in	fects on
placentas of smoking mothers	71:57 Epithelial lesions
71:410 carbonic anhydrase, carbon monoxide	in smokers
inhibition in fetal cord blood of	<b>64</b> :168, 170, 172, 173, 213
smoking mothers	Epithelial tissues age effects on
71:407 carbonic anhydrase, decrease in activity	64:34
in fetal cord blood in smoking moth-	changes in female smokers 64:34
ers 71:409	changes in male smokers
effect of cigarette smoke, in rabbit lungs	64:34
74:104, 105	cigarette smoking and 64:34, 165, 167-173, 189, 213,
and macrophage function, in rabbit lungs,	263-275
74:104, 105	ciliary loss in 64:34
oxidative enzymes, effect of ciliatoxic	in ex-smokers
agents on 67:108	64:34
Epidemiological studies	histopathologic changes in 64:167-173, 231, 263-275
bladder neoplasms and smoking 72:72-74	hyperplasia in
bronchopulmonary diseases and smoking	64:34, 203 hypertrophy caused by nitrogen dioxide
72:38-41;73:36-45 cerebrovascular disease and smoking	69:41
75:29, 30	in nonsmokers 64:189
COPD and smoking	pipe and cigar effects on
74:78-80	64:34

premalignant lesions in 64:34;75:44 see also Bronchial epithelium; Esophageal epithelium Epithelial tumors classification of 64:174 in man 64:146 Epitheliomas of lip, relationship of tobacco use with 71:361 Epoxides suspected carcinogenic agents in cigarette smoke 71:265 Ergonovine effect on blood circulation in laboratory animals with coronary disease 67:62 Esophageal balloon technique 64:292 Esophageal epithelium atypical nuclei in basal cells, male smokers 71:292, 379-380 effect of smoking on 67:36, 150-153 pathological changes by age and smoking history 67:150-162 pathological changes by amount smoked 67:152 pathological changes by smoking classification 67:150-151 pathological changes for male smokers vs. nonsmokers 67:150-153 Esophageal neoplasms 64:37, 212-218, 234 alcohol consumption and smoking in 67:152-153; 72:4, 5, 71; 73:76, 200 frequency in smokers vs. nonsmokers 71:12, 238 geographical factors in 64:133 incidence of, by tobacco use 64:216 incidence of, in Jewish women 64:135 incidence of, in U.S. 64:127 income class gradients in 64:134 induction in animals by nitrosamine 71:292 inhalation patterns and 64:218;73:197 methods and results of retrospective studies of tobacco use in 71:289, 375-378 mortality rates 64:37, 133; 71:289 mortality rates, by amount smoked 67:147, 150 mortality rates, by smoking classification 67:147,150

mortality rates in females 64:131,132 mortality rates in Japanese males by smoking and drinking characteristics 72:71 mortality rates in males 64:130, 132 mortality rates in migrants 64:134 mortality rates in pipe/cigar and cigarette smokers 68:102 mortality ratios, by age 67:150 mortality ratios, by amount smoked 67:150 mortality ratios, by smoking classification 67:150 mortality ratios for cigar, pipe, and cigarette smokers vs. nonsmokers 73:197,200 mortality ratios in 64:148, 149, 217; 71:289-291 mortality ratios in cigarette smokers 64:149 mortality ratios in Japanese male smokers vs. nonsmokers 73:76 mortality ratios in nonwhites 64:218 prospective studies of 64:217 relative risk in cigar, pipe, and cigarette smokers vs. nonsmokers 73:197, 200-202 retrospective studies of 64:212-217 risk gradients in, by amount smoked 64:217,218 risk ratios in 64:213 smoking in etiology of 64:37, 188; 67:33, 150, 151; 71:293; 72:4, 70, 71 summary of previous findings on relationship to smoking 68:89, 90; 74:55 summary of retrospective studies 73:201,202 tobacco tars in 64:218 tobacco use and 64:32, 217, 218 trend in mortality 64:137 urban-rural differences in 64:133 Esophagus effect of benzo(a)pyrene in laboratory animals 67:152-153 histological changes in cigar, pipe, cigarette sinokers vs. nonsmokers 73:200 Esters in cigarette smoke 64:52

Ethane 64:60 Ethnic groups neoplasm risks in 64:134.135 neoplasm sites by 64:134, 135 Ethyl alcohol carcinogenic promoter activity of 64:217 Ethylene 64:60 glycol 64:52 Euphoria . 64:350 **Executive Office of the President** 64:15 Exercise on bicycle ergometer, effect of smoking 73:242, 243 cardiac index, effect of smoking 73:242.243 effect of carbon monoxide exposure 74:11, 12 effect of smoking and smoking abstinence 73:241, 242, 246, 247 effects of CO exposure and increased carboxyhemoglobin levels 75:95,97 influencing factors 73:241, 246, 247 and pulmonary function, smokers vs. nonsmokers 74:99 relationship to mortality rates 64:101 summary of findings and mechanism of action 73:246, 247 on treadmill, effect of smoking 73:243, 245 Ex-smokers atypical nuclei in esophageal epithelium, in male 71:379-380 chronic cough 67:98 decrease of lung neoplasm risk 69:57;75:43 effects of cessation on body weight, blood pressure and hypertension development 75:16-19 effects of cessation on closing volume abnormalities 75:71 effects of cessation on pathologic changes 75:74 histological changes in bronchial epithelium at autopsy 73:74 low birth weight infants of 73:112-114 lung neoplasms in, lowered rates 71:11

lung neoplasms in, prevalence 64:192, 193 mortality rates in 64:36;64:105 mortality rates in, by smoking history 67:8-11 mortality rates in. COPD 71:175 mortality rates in, coronary disease 64:322, 323, 325; 71:46-48 mortality rates in, coronary disease, by smoking history 67:51 mortality rates in, coronary disease, cigarette vs. pipe/cigar smokers 73:172.173 mortality rates in, coronary disease, for men by amount smoked 69:15 mortality rates in, coronary disease, for men, by years stopped smoking 69:15 mortality rates in, coronary disease, for men, compared to nonsmokers 69:15 mortality rates in, gastric ulcer 64:104 mortality rates in, laryngeal neoplasms 64:104 mortality rates in, lung neoplasms 64:104; 71:276; 72:5; 73:71-72 mortality rates in, oral neoplasms 64:104 mortality rates in, stroke, for men, compared to nonsmokers 69:15 mortality ratios in 64:36, 92, 93, 103, 104, 105 mortality ratios in, circulatory disease 64:104 mortality ratios in, ex-cigar smokers 64:94 mortality ratios in, lung neoplasms 71:241-242 mortality ratios in, respiratory disease 64:104 pneumoconiosis incidence in, in miners 64:298 prevalence of respiratory symptoms 73:39 psychosomatic disorders in 64:367 pulmonary fibrosis in 64:274 pulmonary function in 73:39 relative risk in lung neoplasms development 73:71-72 risk ratios in, from neoplasms 64:155, 158, 188 summary of previous findings on health consequences of cessation 75:6 summary of previous findings on relationship to COPD 75:61

survival after treatment for pharyngeal, laryngeal, or oral neoplasms 73:75 thickness of vocal cords in 69:60 Extroversion 64:365, 366 Eye irritation effects of exposure to cigarette smoke, in passive smokers 75:99, 100

Face skin neoplasms of 64:147 Factory workers, mean expiratory flow rates in 64:290 False vocal cords epithelial hyperplasia in 64:271 hyperkeratosis in 64:271 Farmers coronary disease incidence in 64:321 decreased smoking by 64:323 myocardial infarction in 64:323 smoking incidence in 64:187 Fats, saturated 64:322 Fatty acid levels effect of cigar, pipe, and cigarette smoke in dogs 73:216 effect of smoking 73:12 rise in, after smoking 71:36,65 in smokers vs. nonsmokers 71:102 see also Fatty acids; Free fatty acids Fatty acids 64:53 suspected carcinogenic agents of cigarette smoke 71:266 see also Fatty acid levels; Free fatty acids Federal insecticide regulations 64:61 Federal Trade Commission 64:8, 15 Fertility and smoking 69:79-80 Fetal death effect of maternal smoking 64:39, 343; 67:185; 69:77-78; 73:123-135 epidemiological studies, in smokers vs. nonsmokers 73:126-132

Fetus effect of maternal smoking 64:39, 343; 72:5, 83-89 heart beats in, increase in smoking mothers 71:408 morbidity, effect of maternal smoking on 67:186 tissues of, effects of elevated carboxyhemoglobin on 71:407 Fibrosis see Pulmonary fibrosis Filters advantages in reduction of particulates 71:269,275 cellulose acetate 64:59 charcoal, and effect of cigarette smoke on cell cultures 69:62 as a factor in reducing hung neoplasm гisk 74:40-41 reduction of lung neoplasms from, 71:13 Finland blood pressure differences in smokers vs. nonsmokers 71.103 COPD morbidity in smokers in 71:200 coronary death rate in 64:320 lung neoplasm mortality in, relationship to tobacco use 64:176;71:245-246 lung neoplasms in, retrospective study of, methods 71:325.327 peptic ulcer in, methods and results for retrospective and cross section studies of smoking 71:426, 428 risk ratio in 64:127 serum lipid differences in smokers vs. nonsmokers in 71:98.99 smoking and nicotine effects on human blood lipids 71:124 Fires smoking as cause of 64:344, 345;67:187-188 Fitness tests smokers vs. nonsmokers 73:245 Flavors antismoking measures using 64:354 Flax mill workers chronic respiratory diseases in 64:289, 299 Fluoranthene alcoholic solution of, penetrability of esophageal epithelium 71:292

in caffeine solution, effect on esophageal tissue in laboratory animals 67-152-153 in carbon black 64:147 in ethanol, effect on esophageal tissue in laboratory animals 67:152-153 Forced expiratory flow rates 64:288-293 Forced expiratory volume 64:288, 289, 290, 291, 293, 294, 298 decline in smokers, by race 75:72 Formaldehyde 64:60, 61, 268 ciliastatic action of 64:61, 268 ciliatoxic agent 67:107 as suspected contributor to health hazards of smoking 72:145 in tobacco smoke 67:107 toxic action of 64:295 tracheobronchial irritation from 64:266 Formic acid ciliato xic agent 67:108 in tobacco smoke 67:108 Formosa acute effect of cigarette smoke on human pulmonary function in 71:169 Framingham Study 64:291, 323 angina pectoris in 64:325 duration of smoking habit and incidence of CHD 68:17 effect of coffee drinking on mortality in smokers vs. nonsmokers 75:20 epidemiologic study of CHD, CDV, intermittent claudication, and smoking 74:14-16 interaction of smoking and other risk factors in CHD 73:8 morbidity ratios for CHD, by smoking habit 68:18:71:24 mortality rates in 64:324 France bladder neoplasms in, methods and results in retrospective studies of smoking 71:381-383 bladder neoplasms in, retrospective studies

64:219, 220, 221

CHD mortality and morbidity in 71:94,97 cigarette smoke effects on animal tissue in 71:343, 344, 349 COPD mortality of smokers in 71:201 esophageal neoplasms in, retrospective studies of tobacco use 64:214; 71:378 laryngeal neoplasms in, relationship to tobacco use 64:205, 207; 71:355, 357 lung neoplasms in, methods of retrospective study of smoking in 71:326 oral neoplasms in, by type of smoking 64:199, 201 oral neoplasms in, relationship of tobacco use and 71:363 Free fatty acids 64:52 plasma, effect of nicotine, in rats 74:13 plasma, effect of smoking on 69:27 see also Fatty acid levels; Fatty acids Fried foods 64:100 Fume exposure in smokers vs. nonsmokers, by race and sex 75:69.70 Fungi carcinogenic contamination of tobacco 68:92, 93 Fungicides concentration in cigarette smoke 71:265,266 Furfural as suspected contributor to health hazards of smoking 72:145

Ganglia, parasympathetic 64:69, 71, 317, 318 Ganglion cells nicotine effect on 64:69,70 paralysis of 64:69,70 Gas adsorbents carbon granules as 64:61 Gas phase, cigarette smoke 69:63 effect on mucus flow rates in cats 72:47 harmful constituents in 72:143 Gas phase, tobacco smoke 64:60 acetaldehyde in 64:60

64:60 acetylene in 64:60 acrolein in 64:60 ammonia in 64:60 argon in 64:60 butane in 64:60 carbon dioxide in 64:60 carbon monoxide in 64:60 ethane in 64.60 ethylene in 64:60 formaldehyde in 64:60 hydrogen cyanide in 64:60 hydrogen in 64:60 hydrogen sulfide in 64:60 methane in **64**:60 methanol in 64:60 methyl chloride in 64:60 methyl ethyl ketone in 64:60 methyl nitrate in 64:60 nitric oxide in 64:266 nitrogen dio xide in 64:60 nitrogen in 64:60 oxygen in 64:60 phenol in 64:267 propane in 64:60 propylene in 64:60 Gastric acidity effect of smoking on 67:182 Gastric motility 64:340 Gastric neoplasms 64:37, 38, 225-229, 235 decline in mortality from 64:133 geographic factors in 64:133 income class gradients in 64:134 migrant mortality in 64:134

acetone in

mortality rates in 64:130, 133 mortality rates in, in smokers 64:149 mortality rates in, Japanese smokers vs. nonsmokers 74:56,57 mortality ratios in 64:148, 149, 228 prospective studies of 64:227 retrospective studies of 64:225, 226, 227, 228 retrospective studies of, by smoking pattern 64:226, 227 summary of previous findings on relationship to smoking 68:90;74:55 tea drinking and smoking in etiology of 74:56, 57 tobacco tars in 64:228 trends in prevalence of 64:135 U.S. incidence of 64:127 Gastric secretion effect of nicotine 72:97 effect of nicotine in laboratory animals 73:158, 159 effect of smoking 64:340 effect of smoking in ulcer patients 73:157, 158 Gastric ulcers 64:8, 37, 337, 340 healing of, after cessation of smoking 64:337 mortality ratios in 64:37, 113, 337 Gastrointestinal disorders prevalence in cigarette and pipe/cigar smokers 73:222 smoking and 72:5, 6, 97, 98 **General practitioners** coronary disease incidence in 64:321, 322 Genetic factors 64:321,385 alpha-1-antitrypsin deficiency 72:44 alpha-1-antitrypsin deficiency and smoking in COPD development 74:87-90:75:72-74 in bronchitis development 67:102-104, 108-109 cessation of smoking and 64:191 COPD pathogenesis and 71:148, 150-152, 205 coronary disease and 72:18 in cough development 67:102, 111

in emphysema development 67:30, 102-103, 108-109, 111 and heart disease 67:53-54.57 lung neoplasms and 64:167, 232 in respiratory tract disease development 67:30,108 short run changes in, in humans 64:191 smoking and 64:190, 319; 71:5; 72:18, 44 smoking and, in lung neoplasm development 74:37 susceptibility in neoplasm epidemiology 64:190, 191, 192, 193 twin studies, effects of smoking 71:49-52, 99 Genitourinary diseases see Urogenital diseases Genitourinary neoplasms see Urogenital neoplasms Geographic factors neoplasm incidence by 64:133 neoplasm mortality by 64:133 Germany CHD morbidity and mortality in 71:95-96, 97 cigarette smoke inhalation effects on animal respiratory tract in 71:350 laryngeal neoplasms in 64:205 laryngeal neoplasms in, relationship to tobacco use 71.355 laryngeal neoplasms in, retrospective study of 64:206 lung neoplasms in, methods of retrospective study of smoking in 71:323, 325, 326 polonium-210 levels in lungs of smokers in 71:336 smoking and nicotine effects on human blood lipids 71:125 Gestational age effect on perinatal mortality rates in smoking vs. nonsmoking mothers 73:126-132 and low-birth-weight infants, effect of maternal smoking 73:103-106 Gingival neoplasms 64:197, 202 cigar smoking in 64:202 pipe smoking in 64:202 retrospective study of, by type of smoking 64:201

tobacco chewing in 64:202 see also Mouth neoplasms; Oral neoplasms Gingivitis incidence among Danish Royal Marines 69:86 incidence among Dutch Navy recruits 69:86 incidence among U.S. Naval trainees 69:86 smoking and 69:85-86;72:6 Gingivitis, Vincent's relationship to smoking 69:86 Ginseng root 64:355 Glossary terms used in smoking and ventilatory function 71:215 Glucose intolerance as a risk factor in CHD 73:8 Glucose metabolism cardiovascular effects of 68:40,41 and insulin response, alteration effects on myocardial response 71:66 Glutamic acid 64:54 Glutamine 64:54 Glutathione inhibition of smoke cytotoxic action on macrophages 69:42 Glycerol 64:52.62 Glycogen levels in mice lung exposed to cigarette smoke 71:161 Glyoxal 64:53 Goblet cells morphological changes in 64:35, 268, 271 Graphite respiratory tract carcinoma in workers exposed to 71:256 Grief. drug use in 64:353 Grip strength effect of smoking 73:241, 242 Group psychotherapy cure of tobacco habit by 64:354 Growth inhibitors and carcinogenesis 68:92

Guanethidine blockage of nicotine cardiac stimulation Ъy 71:57 Guinea pigs 64:296 induced pulmonary damage in 64:266 lung neoplasm development following chronic nickel carbonyl or dust inhalation 71:256 lungs of, cigarette smoke effects on surfactant activity 71:255 respiratory changes in, exposed to cigarette smoke 71:162 sulfur dioxide effect on 64:266 Habituation 64:350, 352, 354 definition of 64:351 Hamsters benzo(a)pyrene inhalation by, effect of asbestos dust on carcinoma induction 71:162 bladder neoplasms in, fed 2-naphthylamine 71:296 cigarette smoke instillation or implantation effects on tracheobronchial tree of 71:268, 346-348 induced carcinogenesis in 64:166 induced oral neoplasms in 64:202, 203, 204, 232 laryngeal neoplasms following smoke inhalation 71:12 larynx of, effect of cigarette smoke inhalation on 71:281, 284 lung and embryos, effects of cigarette smoke tars on 71:343-344 pulmonary changes from chronic nitro-gen dioxide inhalation 71:220 respiratory tract of, C-14 labeled particulates deposition in 71:281-282 respiratory tract of, cigarette smoke inhalation effects on 71:268, 351 Harvard College alumni study 64:385, 386 student study 64:383 Health Insurance Plan 68:19, 20

myocardial infarction in pipe and cigar smokers under 71:32, 38-39 Heart effect of CO exposure 74:10-12 effect of nicotine 64:318;67:60;71:36;74:13 effect of smoking 64:318; 67:60-62 see also Myocardium Heart disease 64:320 description of 64:320 U.S. mortality rate from 64:25, 317, 320 see also Coronary diseases Heart rate 64:318, 326 effect of catecholamines on, 67:60 effect of CO exposure 74:11, 12 effect of exercise and smoking 73:242-246 effect of nicotine on 67:60;74:13 effect of smoking and coronary disease 67:61;71:45,47 effect of smoking on 67:60 fetal, effect of maternal smoking 71:408 Hematite 64:193 dust, respiratory tract neoplasms in hamsters exposed to 71:348 Hematocrit 64:319 infant, smoking mother effects on 71:407.409 variations in, effect on coronary blood flow 71:66 Hemoglobin 64:319 affinity for oxygen, CO effects on 2,3-diphosphoglycerate control of 71:60-61 effect of smoking on oxygen affinity 69:29 levels, relation to incidence of coronary disease 67:58 risk factor in CHD 68:29 variations in, effect on coronary blood flow 71:66 Hepatomas 64:145,321 Heptachlor 64:62,145 Heredity see Genetic factors

Heterocyclic compounds 64:54 carcinogenic properties in cigarette smoke 71:264.265 Heterocyclic nitrogen compounds carcinogenicity 67:127 in tobacco smoke 67:127 Hexamethonium blockage of nicotine cardiac stimulation by 71:57 High school students smoking in 64:370 Hippocampus nicotine effect on 64:71 Histiocytes 64:269 Histological studies in laboratory animals 73:49, 50 lung neoplasms and smoking 74:38;75:44-46 lung neoplasms in U.S. veterans 73:73 macrophage function and 74:104, 105 in smokers vs. nonsmokers 74:8,49 Holland lung neoplasm mortality rate in 64:176 smoking habits in 64:177 Honolulu Heart Study interaction of smoking and other risk factors in CHD 73:8,9 Hookahs smokers of, laryngeal neoplasm induction in 71:355 Humectants 64:52 Humidity and pathologic effects of exposure to cigarette smoke 75:99 Hungary methods used for retrospective studies of lung neoplasms in 71:328 Hunger 64:355 Hydrocyanic acid as probable contributor to health hazards of smoking 72:144 Hydrogen in gas phase, cigarette smoke 64:60 Hydrogen cyanide 64:60

in cigarette smoke, effects on body oxidative metabolism 71:62 ciliastatic action of 64:61,268 as respiratory enzyme poison 64:60 toxicity of 64:265, 266 Hydrogen sulfide 64:60 as suspected contributor to health hazards of smoking 72:145 Hydrolases reduction of in smokers' alveolar macrophages 69:42-43 Hydroperoxides 64:52,72 Hydroquinone 64:54 bladder neoplasm induction in laboratory animals 67:156 as suspected contributor to health hazards of smoking 72:145 3-Hydroxyanthranilic acid bladder neoplasm induction in laboratory animals 67:156 urinary excretion, smokers vs. nonsmokers 67:156 Hydroxy-cotinine structure of 64:72 Hydroy-coumarin 64:145 3-Hydroxykynurenine bladder neoplasm induction in laboratory animals 67:156 excretion of, smokers vs. nonsmokers 67:156 excretion of, smoking effects on 71:296 Hydroxyproline level in mice lung exposed to cigarette smoke 71:161 Hypercapnia and chronic obstructive bronchopulmonary disease 68:75,76 Hypercholesterolemia and hypoxia, in arteriosclerosis 69:26 incidence in Belgian military men 74:17, 18 incidence in male British business executives, by smoking habit and clinical parameters **73**:11 as a risk factor for coronary heart disease 72:16, 17; 73:8, 9, 11

Hyperchromatic nuclei in epithelial cells of smokers 64:168, 173 Hyperinsulinemia during oral glucose tolerance tests after smoking 68:41 Hyperplasia 64:168, 169, 170, 172, 203, 231 basal cell 64:168, 169, 170, 172, 173, 231 basal cell, and smoking 67:36 betel nut chewing and 64:203 bronchial mucosa, by smoking history in men 67:105 nonspecificity of 64:172 precancerous aspects of 64:166 reversibility of 64:172 Hyperpnea from nicotine 64:70 Hypersensitivity effect in emphysema development 67:111 Hypertension incidence in male Israeli civil servants 74:18 interaction with smoking as risk factor in cerebrovascular disease 73.9 pulmonary, and chronic obstructive pulmonary disease 68:74-76 as a risk factor for coronary heart disease 64:32, 321; 72:16, 17; 73:8, 9 risk of, in smokers vs. nonsmokers 68:22,44 smoker mortality rates in 64:325 smoking effects in 64:325;75:15-19 summary of recent findings 75:33 in women smokers with CHD 68:22 Hypnotism cure of tobacco habit by 64:354 Hypothalamus nicotine stimulation 64:71 Hypoxemia carbon dioxide effects on 71:61.75 and chronic obstructive bronchopulmonary disease 68:75,76 smoking and 72:22 Hypoxia aortic atheromatosis development in rabbits exposed to 71:64

and arteriosclerosis 69:26 carbon monoxide-induced 73:18, 23 effect of nicotine 72:21 experimentally induced in rats 72:21 postoperative, in smokers 71:174, 230 postural, mechanism in asymptomatic smokers vs. nonsmokers 71:147 tissue, carbon monoxide effects on 71:61

Iceland lung neoplasm mortality rate in 64:176 lung neoplasms in, relationship to tobacco smoking 71:244 Immune system response to benzo(a)pyrene-induced lung neoplasms 74:48.49 suppression of immunoglobulin response, by nicotine or water soluble fraction of cigarettes 75:77 Income class lung neoplasm mortality by 64:133, 134 smoking prevalence by 64:362 Indeno(1,2,3-cd)pyrene carcinogenicity 67:127 carcinogenic properties in smoke 67:127;71:265 India 64:205 esophageal neoplasms in, retrospective studies of tobacco use with 64:214, 215; 71:378 laryngeal neoplasms in, relationship to tobacco use 71:355, 356 laryngeal neoplasms in, retrospective studies of 64:205 oral neoplasms in, relationship of tobacco use 71:362,366 oral neoplasms in, retrospective studies of, by type of smoking 64:199.201 relationship of smoking to thrombosis in 71:131 relationship of smoking to tuberculosis in 71:227 smoking and nicotine effects on human cardiovascular system 71:117

Indole, 1-methylpossible initiator in tobacco carcinogenesis 71:265 Industrial carcinogens 64:166 Industrial hazards effect of dust on COPD development 71:175 effect on COPD development in smokers 71:153, 154, 218, 219 Industrial pollution in etiology of bronchitis 67:108 110 in etiology of emphysema 67:108.110 Infant mortality black vs. white smoking mothers 73:129, 132 comparison of stillbirth and abortions in smoking and nonsmoking mothers 71:395, 405,406 differences of birth weight and, in smoking and nonsmoking mothers 71:404 effect of genetic differences and smoking 73:132 effect of maternal smoking 67:185; 69:77,78; 71:415; 72:83, 87;73:123,135 effect of previous obstetrical experience and smoking 73:132 effect of socioeconomic background and smoking 73:131, 132 epidemiological studies in smokers vs. nonsmokers 73:126, 132 factors other than smoking 73:131, 132 low birth weight and 72:86 risk of low-birth-weight infants of smoking vs. nonsmoking mothers 73:126.132 sudden death, relation of smoking and nonsmoking mothers 71:407 Infants development of bronchitis and pneumonia, and maternal smoking 75:103 growth rate, effect of maternal smoking on 69:78 Infectious diseases 64:38, 276, 277, 302 Influenza 64:195, 277, 302 incidence from antibody deficit in smoking 72:109 mortality ratios in 64:276 prevalence in pipe and cigar smokers 73:220, 221

Influenza viruses effect of cigarette smoke on, in mice 68:70.71 effect on dogs inhaling cigarette smoke 71:351 enhancing effect in vitro on oxidized nicotine 69:42 lung neoplasm induction by 64:172 neoplasm induction by 64:166 resistance of mice following cigarette smoke inhalation 71:173 Inhalation 64:91, 187, 188 amount smoked and 64:163 bladder neoplasm prevalence and 64:219, 223, 225 carbon monoxide, effect on blood circulation in coronary disease patients 67:63 as carcinogen application method 64:166 cigarette smoke, and chronic cough 67:97 cigarette smoke, and coronary disease 67:54 cigarette smoke, and mortality 67:7.9 cigarette smoke, effect on blood pressure 67:54 coronary mortality and 64:324 effect of previous smoking habits on patterns of . 73:186, 189 effect on blood circulation in dogs 67.63 esophageal neoplasms and 64:213, 218 frequency-per-puff in cigar and cigarette smokers 73:186, 189 laryngeal neoplasms and 64:209, 212 and lung neoplasms in animals 68:93 lung neoplasms prevalence by 64:159,230 by male smokers, and mortality rate 67:11 as measures of exposure to cigarette smoke 67:15 mortality rate from 64:36, 91, 92, 99, 111 mortality rate, inhalers vs. noninhalers 67:7;68:5 mortality ratios 64:91, 111 particulate retention in 64:264, 350;69:62 personality factors in 64:367

pipe, cigar, and cigarette smokers 73:184, 189 possible determining factors in patterns of 73:183,184 of radon 64:145 risk in, in lung neoplasms 64:188 stimulatory effect from 64:350 of thoron 64:145 tobacco smoke, and bronchogenic carcinoma 67:129 tobacco smoke, and epidermoid carcinoma 67:129 tobacco smoke, and papilloma formation 67:129 summary of previous findings on 75:4 Inorganic compounds 64:141 Insecticides 64:61, 145 aldrin as 64:62 arsenic as 64:61 chlordane as 64:62, 145 DDT as 64:62, 145 Diazinon as 64:62 dieldrin as 64:62 Dylox as 64:62 Endosulfan as 64:62 endrin as 64:62 Guthion as 64:62 heptachlor as 64:62.145 lead arsenate as 64:61 malathion as 64:62, 145 parathion as 64:62, 145 paris green as 64:61 Sevin as 64:62 TDE as 64:62, 145 Insoluble particles clearance mechanisms 64:267 Insufflation application of carcinogens by 64:166

Insurance policyholders breathlessness in 64:287 Intelligence quotient 64:370 Intermittent claudication decrease in exercise time after exposure to CO 75:28 effects of coffee drinking and cigarette smoking 75:20 smokers vs. nonsmokers 72:22, 26 smoking and 73:21 smoking as a major risk factor 74:14-16 International Cooperative Study interaction of smoking and other risk factors in CHD 73:9 International Statistical Classification of Diseases, Injuries, and Causes of Death 64:101 Intestinal neoplasms 64:103 Intestinal tone. tobacco effect on 64:355 Intratracheal injections application of carcinogens by 64:166 Involuntary smoking see Passive smoking Ionized radiation neoplasm induction by 64:142, 143 threshold levels in 64:143 Ireland acute effect of cigarette smoke on human pulmonary function in 71:168 CHD mortality and morbidity in 71:96 CHD mortality and morbidity in, smokers and nonsmokers in 71:94 lung neoplasms in, methods of retrospective study of smoking in 71:328 maternal smoking and infant weight in 71:399 methods used in study of smoking and human pregnancy 71:394, 396 Northern, mortality rates from COPD 71:144 occupational exposure and smoking relationships to COPD in 71:218 relationship of lung neoplasms to smoking, air pollution and residence in 71:218 serum lipid differences in smokers vs. nonsmokers in 71:99

smoking and nicotine effects on human peripheral vascular system 71:133 smoking relationship to thrombosis in 71:130 Iron oxide 64:166 Irritants tissue tolerance to 64:353 Ischem ia 64:319 Ischemic heart disease see Coronary disease Isomethylnicotinium ion structure of 64:72 Isoparaffins 64:51 Isoprene 64:52 Isoprenoids . 64:49, 51 structural formula of 64:49 Isopropyl oil lung neoplasm risk from 64:193 Israel cigarette smoke effects on animal embryos in 71:343 mortality rates from COPD in 71:140 Isuprel aerosol 64:292,293 Italy human experimental data on smoking and pregnancy 71:409 prohibition of advertising in 64:8 serum lipid differences in smokers vs. nonsmokers in 71:100 tracheobronchial tree changes in smokers and nonsmokers in 71:263 Japan bladder neoplasms in, methods and results in retrospective studies of smoking 71:382, 384 CHD mortality

kidney and bladder neoplasms of smokers in 71:295 lung neoplasms, mortality of smokers and nonsmokers in 71:243 lung neoplasms, retrospective smoking study, methods of 71:326,328 mortality ratios, esophageal neoplasms in 71:291 mortality ratios, kidney neoplasms, smokers vs. nonsmokers 73:77 mortality ratios, pancreatic neoplasms in cigarette smokers 71:298 neoplasm risk in 64:127 relationship of lung neoplasms to smoking, air pollution, and residence in 71:255 "Tokyo-Yokohama asthma" 64:276 Jena autopsy records in 64:150 Jews esophageal neoplasms in, in women 64:135 gastric neoplasms in 64:135 increased smoking among, in women 64:363 Job changing smoker prevelance of 64:363 Johns Hopkins student study 64:384 Joint Tuberculosis Society of Great Britain 64:6

Keratin oversecretion of, in stomatitis nicotina 64:271 Keratosis, senile 64:203 Keto-acids 64:53 Ketoamide structure of 64:72 Ketones 64:52 Khat 64:349 Kidney neoplasms epidermoid, associated with cigarette smoking 69:60 mortality rates in U.S. 71:296 mortality ratios in 64:148, 149

166

64:320

71:96

71:343

71:378

lung tissue in

CHD mortality and morbidity in

studies of tobacco use in

cigarette smoke effects on human fetal

esophageal neoplasms in retrospective

mortality ratios, Japanese men and women, smokers vs. nonsmokers 73:77 mortality trends in 64:137.149 relationship of tobacco use and 71:13, 299 in smokers and nonsmokers 71:238, 294-295 smoking and 69:60.64:73:77.78 see also Urogenital neoplasms Korea relation of human pulmonary histology and smoking in 71:255 tracheobronchial tree changes in smokers and nonsmokers of 71.259 Kreyberg classification comparison with World Health Organization classification 64:174 in lung neoplasms 64:35, 159, 173 Kreyberg study lung neoplasms and smoking 69:55-56

Labeling of tobacco products 64:8 Laboratory techniques for induction of experimental neoplasms 69:63-64 Laborers coronary incidence in 64:321 Lactate metabolism effect of smoking, in patients with angina pectoris 73:13 Lactation effect of maternal smoking 73:138-141 effect of maternal smoking, summary of findings 73:141 epidemiological studies 73:138 experimental studies 73:138, 139 Lactones carcinogenicity of 64:145 suspected carcinogenic agents in cigarette smoke 71:265 Laparotomy postoperative pulmonary complications following, in smokers vs. nonsmokers 71:174 Laryngeal neoplasms 64:37, 205-212, 233, 234; 71:12, 237-239, 281

alcohol consumption in 64:210 development in hamsters following cigarette smoke inhalation 71:239 development in smokers 71:12, 281 dose effect in 64:210, 234 effect of cessation of smoking on 67:149 epidemiological studies 72:68 extrinsic origin of 64:211, 212 incidence in males and females, by age 68:101, 102 incidence of secondary primary, in smokers vs. nonsmokers 75:50 income class gradients in 64:134 inhalation effects in 64:209 inhalation patterns and, 73:193 intrinsic origin of 64:211, 212 mortality rates 64:37, 133, 135, 210; 71:277 mortality rates, by age 67:149 mortality rates, by age for men 67:148 mortality rates, by amount smoked 67:149 mortality rates, by smoking classification 67:147, 149 mortality rates, for women 64:134;67:153 mortality rates, in smokers vs. nonsmokers 71:237-238 mortality rates, in United States by age 67:148 mortality rates, in United States by sex 67:148 mortality ratios 64:113, 148, 149; 71:277-279 mortality ratios, and smoking 67:33-35, 148-149 mortality ratios, by age 67:149 mortality ratios, by age for men 67:148 mortality ratios, by amount smoked 67:149 mortality ratios, by smoking classification 67:149 mortality ratios, cigar smokers vs. nonsmokers 67:35 mortality ratios for pipe, cigar, and cigarette smokers vs. nonsmokers 73:193, 196, 197 mortality ratios in, in females 64:132